ATROPHIC VAGINITIS
Abstract
Background: Due to the defficiency of sex hormone estrogen after the menopause, the quality of woman's life dramatically decreases. Atrophic vaginitis in particular is a frequent cause of problems in these women's sex life.
Methods: The gynecologist can detect the problems related to atrophic vaginitis using directed medi- cal history; clinical picture is also easily recognized. Atrophic vaginits is treated with locally applied hormone preparations, 17 beta Estradiol in the form of vaginal tablets having been proven as the safest providing the highest compliance.
Safety, efficinecy and good compliance of 17 beta Estradiol vaginal tablets in the treatment of atrophic vaginitis was also confirmed by Slovene gyencologists in an observational study. In the next step we used a survey to evaluate the extent of sexual activity, their attitude to sexuality, and their subjective notion of the treatment they received from their gynecologists among the menopausal women coming to outpatient clinics.
Conclusions: The quality of sexual life in women with atrophic vaginitis can be improved by local hormone treatment. A proactive approach is required, using a directed medical history concerning sexual activity. It is clear that for too many postmenopausal women sexuality is still a taboo which they will reluctantly talk about.
Downloads
References
Bachmann GA. Urogenital aging: an old problem newly recog- nized. Maturitas 1995; 22 suppl: S1–5.
Iosif CS, Bekassy Z. Prevalence of genito-urinary symptoms in the late menopause. Acta Obstet Gynecol Scand 1984; 63; 257–60.
Hextal A. Oestrogen and lower urinary tract function. Maturitas 2000; 36: 83–92.
Šimunić V, Banović I,. Ciglar S, Jeren L, Pavičić Baldani D, Šprem M. Local estrogen treatment in patients with urogenital symp- toms. Gynecol Obstet 2003; 82: 187–197.
Widhom O,Vartiainen E, Stenman UH, Wahlstrom T. The vagi- nal absorbtion of estriol and dienoestrol in post-menopausal woman. Arch Gynecol 1985; 237 Suppl 1: 152.
Utian WH, Schiff I. NAMS-Gallup survey on women’s knowledge, information sources, and attitudes to menopause and HRT. Menopause 1994; 1: 39–44.
Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006: CD001500.
Vrabič Dežman L. Priporočila za lokalno hormonsko zdravljenje pri bolnicah z atrofičnim vaginitisom. Isis 2008; 17: 74–6.
Register zdravil Republike Slovenije XI, 2008. 10. Gelfand M. Sexuality among older women. J Women Health
Gend Based Med 2000, 9 Suppl 1: S15–20. 11. Rioux JE, Devlin MC, Gelfand MM, Steinberg WS, Hepburn
DS. 17-beta estradiol vaginal vablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrofic vaginitis. menopause 2000; 7: 156–61.
Barlow DH, Samsioe G, van Geelen JM. A study of European women’s experience of the problems of urogenital ageing and its management. Maturitas 1997; 27: 239–47.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
